Matches in SemOpenAlex for { <https://semopenalex.org/work/W137885780> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W137885780 endingPage "7" @default.
- W137885780 startingPage "S33" @default.
- W137885780 abstract "The tolerability of reboxetine was evaluated in 2613 adult (aged 18-65 years) or elderly (aged > 65 years) patients with depressive illness treated with reboxetine, comparator agents or placebo, who entered both short- and long-term, controlled and uncontrolled clinical trials. The reboxetine adverse-event profile in acute depression was established by comparison with placebo in 746 patients. Overall, 69% of 373 patients treated with reboxetine experienced adverse events compared with 57% of 373 patients in the placebo group. The majority of adverse events were moderate in severity, and discontinuation because of adverse events was low and comparable in both the reboxetine (8%) and the placebo (7.5%) group. When compared with imipramine, reboxetine was better tolerated. Most side-effects were less common in the reboxetine than the imipramine cohort, and fewer patients receiving reboxetine (10% in adult patients; 11% in elderly patients) discontinued treatment because of adverse events than those receiving imipramine (14% in adult patients; 16% in elderly patients). Compared with fluoxetine, the total frequency of adverse events was similar in reboxetine-treated patients (67%) and fluoxetine-treated patients (65%). In the fluoxetine group, 7% discontinued because of adverse events compared to 12% in the reboxetine group and 12% in the corresponding placebo group. In a 12-month placebo-controlled study, discontinuation because of adverse events in both groups was low (reboxetine 4%; placebo 1%), and the total frequency of adverse events was only marginally higher with reboxetine (28%) than with placebo (23%). Overall, no consistent changes were found in laboratory tests or electrocardiogram recordings and there was no indication of withdrawal symptoms upon abrupt reboxetine discontinuation. Reboxetine, a novel selective noradrenaline reuptake inhibitor, is well tolerated by adults and the elderly during short- and long-term treatment for depression." @default.
- W137885780 created "2016-06-24" @default.
- W137885780 creator A5051673378 @default.
- W137885780 date "1997-01-01" @default.
- W137885780 modified "2023-10-17" @default.
- W137885780 title "Reboxetine: a review of antidepressant tolerability." @default.
- W137885780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9438231" @default.
- W137885780 hasPublicationYear "1997" @default.
- W137885780 type Work @default.
- W137885780 sameAs 137885780 @default.
- W137885780 citedByCount "26" @default.
- W137885780 countsByYear W1378857802013 @default.
- W137885780 countsByYear W1378857802016 @default.
- W137885780 countsByYear W1378857802018 @default.
- W137885780 crossrefType "journal-article" @default.
- W137885780 hasAuthorship W137885780A5051673378 @default.
- W137885780 hasConcept C126322002 @default.
- W137885780 hasConcept C142724271 @default.
- W137885780 hasConcept C170493617 @default.
- W137885780 hasConcept C197934379 @default.
- W137885780 hasConcept C204787440 @default.
- W137885780 hasConcept C27081682 @default.
- W137885780 hasConcept C2775864247 @default.
- W137885780 hasConcept C2776134451 @default.
- W137885780 hasConcept C2778375690 @default.
- W137885780 hasConcept C2778715236 @default.
- W137885780 hasConcept C2779144063 @default.
- W137885780 hasConcept C2779145073 @default.
- W137885780 hasConcept C2779177272 @default.
- W137885780 hasConcept C2780051608 @default.
- W137885780 hasConcept C2780467756 @default.
- W137885780 hasConcept C2781161787 @default.
- W137885780 hasConcept C31487548 @default.
- W137885780 hasConcept C42219234 @default.
- W137885780 hasConcept C71924100 @default.
- W137885780 hasConceptScore W137885780C126322002 @default.
- W137885780 hasConceptScore W137885780C142724271 @default.
- W137885780 hasConceptScore W137885780C170493617 @default.
- W137885780 hasConceptScore W137885780C197934379 @default.
- W137885780 hasConceptScore W137885780C204787440 @default.
- W137885780 hasConceptScore W137885780C27081682 @default.
- W137885780 hasConceptScore W137885780C2775864247 @default.
- W137885780 hasConceptScore W137885780C2776134451 @default.
- W137885780 hasConceptScore W137885780C2778375690 @default.
- W137885780 hasConceptScore W137885780C2778715236 @default.
- W137885780 hasConceptScore W137885780C2779144063 @default.
- W137885780 hasConceptScore W137885780C2779145073 @default.
- W137885780 hasConceptScore W137885780C2779177272 @default.
- W137885780 hasConceptScore W137885780C2780051608 @default.
- W137885780 hasConceptScore W137885780C2780467756 @default.
- W137885780 hasConceptScore W137885780C2781161787 @default.
- W137885780 hasConceptScore W137885780C31487548 @default.
- W137885780 hasConceptScore W137885780C42219234 @default.
- W137885780 hasConceptScore W137885780C71924100 @default.
- W137885780 hasIssue "4 Suppl" @default.
- W137885780 hasLocation W1378857801 @default.
- W137885780 hasOpenAccess W137885780 @default.
- W137885780 hasPrimaryLocation W1378857801 @default.
- W137885780 hasRelatedWork W137885780 @default.
- W137885780 hasRelatedWork W1968895338 @default.
- W137885780 hasRelatedWork W1969966668 @default.
- W137885780 hasRelatedWork W1989210017 @default.
- W137885780 hasRelatedWork W2034112753 @default.
- W137885780 hasRelatedWork W2036930192 @default.
- W137885780 hasRelatedWork W2063767287 @default.
- W137885780 hasRelatedWork W2148495812 @default.
- W137885780 hasRelatedWork W2157547590 @default.
- W137885780 hasRelatedWork W3033299995 @default.
- W137885780 hasVolume "11" @default.
- W137885780 isParatext "false" @default.
- W137885780 isRetracted "false" @default.
- W137885780 magId "137885780" @default.
- W137885780 workType "article" @default.